var dict = {
    index_title_1: {
        zh: "源自瑞典的医疗技术",
        en: "Original Technology"
    },

    index_menu: {
        zh: "菜单",
        en: "Menu"
    },

    index_nav_1:{
        zh: "主页",
        en: "Home Page"
    },

    index_nav_2:{
        zh: "关于我们",
        en: "About Us"
    },

    index_nav_3:{
        zh: "公司目标",
        en: "The Vision"
    },

    index_nav_4:{
        zh: "执行总裁简介",
        en: "CEO of CarpoNovum"
    },

    index_nav_5:{
        zh: "生产",
        en: "Production"
    },

    index_nav_6:{
        zh: "技术与产品介绍",
        en: "Technology and Products"
    },

    index_nav_7:{
        zh: "外科手术步骤",
        en: "Surgical procedure"
    },

    index_nav_8:{
        zh: "产品介绍",
        en: "Products"
    },

    index_nav_9:{
        zh: "质量与法规",
        en: "Quality and Regulatory"
    },

    index_nav_10:{
        zh: "公司",
        en: "Company"
    },

    index_nav_11:{
        zh: "董事会成员",
        en: "Board of Directors"
    },

    index_nav_12:{
        zh: "组织结构",
        en: "Organization "
    },

    index_nav_13:{
        zh: "临床试验",
        en: "Clinical Trials"
    },

    index_nav_14:{
        zh: "教学视频",
        en: "Videos"
    },

    index_nav_15:{
        zh: "联系我们",
        en: "Contact Us"
    },

    index_nav_16:{
        zh: "新闻",
        en: "News"
    },

    home_footer_design: {
        zh: "网站设计:",
        en: "Website Design"
    },

    home_footer_company: {
        zh: "郁达信息技术有限公司",
        en: "Yuda Information & Technology Co.Ltd"
    },

    home_footer_ICP: {
        zh: "沪ICP备17033915号-1",
        en: "沪ICP备17033915号-1"
    },

    home_button: {
        zh: "了解我们",
        en: "To Know Us"
    },

    home_about_us: {
        zh: "关于CarpoNovum",
        en: "About CarpoNovum"
    },

    home_about_us_2: {
        zh: "源自瑞典",
        en: "From Sweden"
    },


    home_carponovum_1: {
        zh: "CarpoNovum 是一家专注于结直肠外科吻合器研发和生产的瑞典医疗器械公司，总部位于瑞典哈姆斯塔德（Halmstad）市。",
        en: "CarpoNovum AB is a Swedish company based in Halmstad, focused on developing a new generation of surgical instruments, used throughout cancer surgery in the colon and rectum."
    },

    home_carponovum_2: {
        zh: "在结直肠癌手术器械上的大胆创新是CarpoNovum一直努力并已逐步达成的目标。包括医疗、人体工程设计、机械材料领域等多方面资深研发人士经十余年不断完善，已构建出一整套先进的产品家族。该系列从理念到临床运用及实际效果均突破传统设计的局限性，让更安全、更方便、更简洁、更快速成为可能。",
        en: "CarpoNovum has expert competence of cancer surgery in house and therefore a very good understanding of what is needed to radically improve the surgical instruments and preoperative conditions in order to reduce complication rates. After over 10 years of research and product development, we now have surgical instruments aimed to be used at cancer surgery in the large intestine."
    },

    home_carponovum_3_title: {
        zh: "CE 产品认证",
        en: "CE Product Certification"
    },

    home_carponovum_3: {
        zh: "目前，在系列产品中，CREX FixAid已经通过欧洲CE安全认证并运用于欧洲不同地区；CREX LapAid已通过中国国家质量检测机构认证，并在临床试验阶段取得非常满意可靠的反馈结果；CREX RectoAid 顺利通过国家级检测机构安全认证，近期亦将很快投入临床试验研究评估。",
        en: "The CREX FixAid product is CE marked and introduced on the market in Europe. The CREX LapAid and RectoAid are only for clinical studies."
    },

    home_carponovum_3_suffix: {
        zh: "了解更多CREX产品信息",
        en: "Know more about CREX"
    },

    home_company_1: {
        zh: "公司历史",
        en: "Company History"
    },

    home_company_2: {
        zh: "CarpoNovum公司成立于2006年，同期引入第一批外部股东。LUIS（Lunds Universitet Innovations System AB，隆德大学创新孵化公司）成为公司的主要合作伙伴，不仅为公司提供资金支持，还提供了人才，发展运营建议等其他重要资源。同年秋天，CarpoNovum公司荣获多项瑞典创新大奖。",
        en: "CarpoNovum was initiated in 2006 and the first external shareholders entered the company the same year. LUIS (Lunds Universitet Innovations System AB) became a major partner contributing not only with funding but also with competence and advice. During autumn CarpoNovum was awarded with Öhrlings PriceWaterHouseCoopers and LUIS’s Innovation awards."
    },

    home_company_3: {
        zh: "2007年，CONNECT Skåne的一批商业天使投资人为公司提供了加速发展的资金，几位有过医疗器械行业高管背景的商业天使进入公司董事会。 CarpoNovum还相继获得了Connect Sweden最成功的公司和国家创造开发大奖。",
        en: "In 2007 a group of investors from the CONNECT Skåne Business Angels’ network gave the company the means to accelerate its development. Several business angels with senior positions in MedTech companies entered the Board of Directors. CarpoNovum was also awarded both the award of the most successful company in the Connect Sweden network and the national Skapa Development Award."
    },

    home_vision_1: {
        zh: "公司愿景",
        en: "The vision"
    },

    home_vision_2: {
        zh: "CarpoNovum公司立足于伤口愈合的基础研究和工程技术的创新实力，致力于为广大结直肠外科医生与患者提供更先进的肠吻合器，以期达到：",
        en: "CarpoNovum has set the goal to change the perception of how to create an anastomosis. Fundamental studies in wound healing and amazing creativity in the art of engineering have paved the way for the vision. What the colorectal surgeon and patients would benefit from is a procedure which:"
    },


    home_vision_3: {
        zh: "更快速可靠的肠吻合",
        en: "Creates a fast and reliable anastomosis."
    },

    home_vision_4: {
        zh: "更低的发病率和死亡率",
        en: "Reduces morbidity and mortality."
    },

    home_vision_5: {
        zh: "避免保护性造口",
        en: "Avoids the need for a protective stoma."
    },

    home_vision_6: {
        zh: "及时发现手术后潜在的渗漏",
        en: "Detects potential leakage after surgery."
    },

    home_vision_7: {
        zh: "保持术后肠道弹性",
        en: "Maintains elasticity of the intestine after surgery."
    },


    home_vision_8: {
        zh: "激发和改善愈合过程的结果",
        en: "Has the possibility to stimulate, and to improve the outcome of the healing process."
    },
    home_vision_9: {
        zh: "能在肠吻合术后监测并确定吻合口愈合情况",
        en: "Monitors and determines the status of the circulation in the intestinal ends before creating the anastomosis."
    },
    home_vision_10: {
        zh: "手术操作简单易学，安全可靠。",
        en: "The surgical procedure should be short, user-friendly and easy to learn."
    },


    home_ManagementTeam_title_1: {
        zh: "公司执行总裁介绍",
        en: "CEO of CarpoNovum"
    },

    home_ManagementTeam_title_2: {
        zh: "安德斯·格伦博格\n Anders Grönberg",
        en: "Anders Grönberg"
    },

    home_ManagementTeam_title_3: {
        zh: "公司执行总裁",
        en: "CEO of CarpoNovum"
    },

    home_ManagementTeam_title_4: {
        zh: "格伦博格医生/博士自2006年起担任公司执行总裁，公司产品专利所有者 ，公司事务总负责人。 ",
        en: "CEO of CarpoNovum since 2006. CarpoNovum company product patent owner, corporate affairs general manager."
    },

    home_ManagementTeam_1: {
        zh: "曾做过瑞典萨博（SAAB）飞机制造工业设计工程师，专注于战斗机着陆装置的相关设计",
        en: "Former design engineer at SAAB aircraft industry in Linköping, focused on landing gear on fighter jets."
    },

    home_ManagementTeam_2: {
        zh: "还为瑞典Tydraul重工设计过重型卡车后轴",
        en: "Former design engineer at Tydraul Sweden focused on rear axle at heavy duty trucks."
    },

    home_ManagementTeam_3: {
        zh: "医学博士（1991）微生物学博士（1992）",
        en: "Doctor in Microbiology (PhD) (1992)."
    },

    home_ManagementTeam_4: {
        zh: "1997年起专攻结直肠外科手术，2006年起任瑞典赫尔辛堡市结直肠门诊主任医师。",
        en: "Speicalist in colorectal surgery since 1997. Chief physician of the colorectal surgery 2006"
    },

    home_BoardOfDirectors_1: {
        zh: "董事会成员",
        en: "Board of Directors "
    },

    home_BoardOfDirectors_2_title:{
        zh: "尤纳斯·古利克森（Jonas Gulliksson）",
        en: "Jonas Gulliksson"
    },

    home_BoardOfDirectors_2: {
        zh: "董事会主席，律师，瑞典律师协会成员，欧洲商标和设计律师。古利克森先生有超过40年的瑞典国家和国际专利，知识产权纠纷及仲裁方面的工作经验。他是古利克森律师事务所（Advokatbyrån Gulliksson AB）的创始人以及高级合伙人，同时也是斯特朗姆&古利克森事务所（Ström & Gulliksson AB）的公司创始人及董事会成员。",
        en: "Chairman of the Board. Advocate. Member of the Swedish Bar Association. European Patent Attorney. European Trademark and Design Attorney. Mr. Gulliksson has over 40 years of experience from national and international patent and IP-litigation and arbitration. He is a Senior Partner and founder of Advokatbyrån Gulliksson AB as well as Founder and Member of the Board of Directors of Ström & Gulliksson AB."
    },

    home_BoardOfDirectors_3_title:{
        zh: "安德斯·格伦博格（Anders Grönberg）",
        en: "Anders Grönberg"
    },

    home_BoardOfDirectors_3: {
        zh: "格伦博格博士于1991年取得瑞典乌普萨拉大学医学博士学位，此后作为外科医生在临床前线工作超过十五年， 拥有十多年结直肠癌症外科手术专科经验，2006年获任瑞典赫尔辛堡市结直肠门诊高级医师。安德斯博士还同时拥有微生物学博士学位，以及五年多设计工程师的工作经历。\n",
        en: "Member of the Board. Dr. Grönberg qualified as MD from the University of Uppsala 1991 and has over 15 years surgical practice with 10 years focused on colorectal cancer surgery. He was appointed as senior clinician at the Colorectal Surgical Clinic, Helsingborg Hospital, in 2006. Anders Grönberg also holds a PhD in microbiology as well as degree in mechanical engineering and has even worked as a design engineer for 5 years."
    },

    home_BoardOfDirectors_4_title:{
        zh: "丹尼斯·维也特-雅克布森（Denis Viet-Jacobsen）",
        en: "Denis Viet-Jacobsen"
    },

    home_BoardOfDirectors_4: {
        zh: "董事会成员。毕业于哥本哈根商学院，继而就读欧洲管理学院获得工商管理硕士。他有着长期私募资金投资经验，并合伙创立了“阿尔特资金合伙人”，一家顶尖的中型私募资金投资公司，其业务主要集中于投资和发展北欧地区的中型企业。此前丹尼斯曾在伦敦和巴黎的Braxton Associates公司担任投资战略顾问，在Intermediate Capital Group从事了八年欧洲，亚洲，大洋洲和美国地区投资组合管理工作。\n",
        en: "Chairman of the Board. Mr. Viet-Jacobsen studied at Copenhagen business school and subsequently at EAP, European Management School, where he obtained his MBA. He has long standing experience of private equity investing and co-founded Altor Equity Partners in 2002-03, a leading mid market private equity firm, focused on investing in and developing medium sized companies in the Nordic region. Prior to that he spent 8 years with Intermediate Capital Group, the leading independent mezzanine provider with investment portfolios in Europe, Asia Pacific and the US. He has also worked as a strategy consultant with Braxton Associates in London and Paris.."
    },

    home_BoardOfDirectors_5_title:{
        zh: "汉斯·司嘉林（Hans Skalin）",
        en: "Hans Skalin"
    },

    home_BoardOfDirectors_5: {
        zh: "董事会成员。司嘉林先生曾任宜家国际发展集团总裁和总法律顾问， 创建了“宜家国际发展公司”（Inter IKEA Systems BV），并担任执行总裁和主席。宜家国际发展公司是“宜家”理念的拥有者和全球授权经营者 。 他还是宜家国际发展公司，INGKA集团和IKANO集团以及其他外部公司与机构的董事会成员。\n",
        en: "Member of the Board. Mr. Skalin has worked as Director and General Counsel for the Inter IKEA Group, responsible for the legal structure within the Kamprad sphere in general and for the creation of Inter IKEA Systems B.V.- owner and worldwide franchisor of the IKEA Concept – as CEO and Chairman in specific. He is also a member of the board of companies within the Inter IKEA, the INGKA and the IKANO Groups, as well as external companies and organizations."
    },

    home_BoardOfDirectors_6_title:{
        zh: "拉斯-彼得·哈尔冰（Lars-Peter Harbing）",
        en: "Lars-Peter Harbing"
    },

    home_BoardOfDirectors_6: {
        zh: "董事会成员。哈尔冰先生是一位资深的国际高管，在多个领域具有全面的综合的业务经验。 他曾在美国，中东，非洲，亚太和拉丁美洲的多家知名医疗器械公司就职过。 他在强生公司工作超过十年，担任过该公司EMEA地区（欧洲，中东和非洲地区）的大区总监。 自2009年以来，他将工作重点放在了瑞典本地公司董事会，担任各公司的策略顾问。\n",
        en: "Member of the Board. Mr. Harbing is a senior international executive with global experience in all facets leading fully integrated businesses. His global experiences include high profile medical companies in the USA, Middle East, Africa, Asia Pacific and Latin America. He has worked for Johnson & Johnson in various positions between 1998 – 2009, most recently as President EMEA – Hamburg/Germany. Since 2009 he has been focused on local company boards as a consultant business strategist."
    },

    home_BoardOfDirectors_7_title:{
        zh: "本特·湖霍尔姆（Bengt Sjöholm）",
        en: "Bengt Sjöholm"
    },

    home_BoardOfDirectors_7: {
        zh: "董事会成员，市场与业务发展战略顾问。本特·湖霍尔姆在医疗器械行业工作多年，尤其熟悉制药和医院的运作情况。本特在瑞典著名医疗器械公司Getinge担任集团高层领导超过10年。他同时也是一家康乐事业公司Tylö Group和一家骨科矫形医院Movement Medical的执行总裁，兼任多家公司的董事会成员。本特目前正在做一个有关创新医院管理的项目。",
        en: "Board member, Market analysis and Business Strategy. Bengt Sjöholm has long experience from the Medtech industry, essentially within the pharmaceutical and hospital sectors. Bengt held leading positions in the Getinge Group, being a part of the group management for more than 10 years. He was also CEO of Tylö group, a company within the wellness business and Movement Medical AB, an orthopedic hospital, now a part of the Capio group. Bengt is currently involved in creating a new concept for hospital management, Hälsostaden. Bengt is Member of the Board of Mentice AB, Texor Ab and Cellink AB."
    },

    home_BoardOfDirectors_8_title:{
        zh: "海拉德·卡斯特勒（Harald Castler）",
        en: "Lars-Peter Harbing"
    },

    home_BoardOfDirectors_8: {
        zh: "董事会成员，市场与业务发展战略顾问。海拉德·卡斯特勒是瑞典著名医疗器械公司Getinge 公司的高层管理人员，在该公司工作已经超过30年历史，担任过各种不同的职位，主攻营销与市场方向，从2017年4月开始，主要负责拓展公司生命科学领域业务。海拉德自2017年开始担任CarpoNovum公司董事会成员，兼任Halmstad大学的理事会主席。海拉德毕业于隆德大学，获理学硕士学位。",
        en: "Board member, Market analysis and Business Strategy. Harald Castler is a director of Getinge AB and member of it’s executive management team. He has worked for the company for almost 30 years and held several positions, mainly in sales and marketing. Since April 2017, Harald has the global responsibility to build up the new business area Getinge Life Science. Chairman of the board at Halmstad University 2017-present. Board member at CarpoNovum and Bomill AB 2014-2017. Mr Castler holds a Master of Science from Lund University."
    },

    home_Orgnisation_1: {
        zh: "组织结构",
        en: "Orgnisation"
    },

    home_Orgnisation_2: {
        zh: "公司组织结构如下图所示：",
        en: ""
    },

    home_Partners_1: {
        zh: "生产",
        en: "Production"
    },


    home_Partners_2: {
        zh: "LapAid 和RectoAid 在2015年春天获得了欧洲CE合格认证。当时有少量的产品样品是由瑞典，丹麦和爱尔兰的专业公司制造的。后来，为了尽可能降低生产成本和提高产量，公司将部分产品进行了生产外包。迄今为止，公司一直在保证高质量的前提下，努力降低产品的成本。不过，目前公司产品的价格相比其它“大规模批量生产”的医疗器械而言还是略高一些。\n",
        en: "In spring 2015 it was pointed out to CE (Conformité Européenne) mark LapAid and RectoAid. At this point our products where well functional but small series of prototypes manufactured by highly specialized companies in Sweden, Denmark and Ireland. Since than we have focused on reducing costs and moved most of the activities to “mass production sites” elsewhere in the world to gain lower price and larger volumes. The price of our devices is getting closer to “mass production price” but it is still some years left before we are down to acceptable prices with the same high quality. \n"
    },

    home_Partners_3: {
        zh: "Elos 医疗器械公司隶属于Westergyllen集团，是欧洲最大的外科手术器械与骨科植入器材的制造生产商。Elos 医疗器械公司依据合约商定规格负责为CarpoNovum公司生产FixAid® 与RapAn®系列产品",
        en: "Part of the Westergyllen Group. One of Europe’s foremost manufacturers of surgical and orthopaedic implants and instruments. ELOS manufactures FixAid® and RapAn® in accordance with pre-agreed detailed specifications."
    },

    home_Partners_4: {
        zh: "优质高效的产品制造",
        en: "Subcontractors"
    },

    home_Partners_5: {
        zh: "CarpoNovum公司始终依照ISO9001,ISO13485等相关管理体系标准严格审查甄选产品组件供应商，使其在取得生产授权的认证资质后能高效精准地完成每批次产品组件。除了关键部分在欧洲大陆进行生产加工外，近年来CarpoNovum公司也将一部分产品组件的加工任务交给中国最优秀的制造商。目前，已有7家顶尖在华制造企业获得加工授权。为了保证高标准高质量，公司对每批组件均进行百分百验证，并不定期对厂家进行飞行检查。",
        en: "Our company has over the last year built up a way to \"auditing\" suppliers that meet high production requirements and have its own quality certificate. The production of some parts has been moved from Europe to China. Numbers of crucial parts are still manufactured in Sweden. A dedicated person has been hired solely to find the best suppliers in China. Today we have seven subcontractors that we trust and that is implemented in our quality system. The quality on our product keep a very high standard and our demands on our subcontractors are very high. "
    },

    home_Partners_6: {
        zh: "Nolato 医用橡胶公司协助世界各地领先的医疗技术公司开发定制注射成型精密部件。CarpoNovum公司产品中的O型环和密封环由Nolato 医用橡胶公司根据合约商定的规格负责制造完成。",
        en: "Nolato Medical Rubber assists leading medical technical companies around the world to develop customised injection-moulded precision components. The O-rings and sealing rings are manufactured for CarpoNovum, in accordance with pre- agreed detailed specifications."
    },

    home_Partners_7: {
        zh: "验证完善的清洁流程",
        en: "Cleaning process in house"
    },

    home_Partners_8: {
        zh: "CarpoNovum 公司根据相关标准建立了一整套完善的清洁流程。该流程已经验证，并保障了产品组件在组装前已达到医疗级专业清洁标准。",
        en: "CarpoNovum has its own validated washing process in house which gives us the possibility to use suppliers that do not have the knowledge of this process. To have our own washing process has therefore been a strategic goal to reduce production costs. "
    },

    home_Partners_9: {
        zh: "信心保证的欧洲装配",
        en: "Final assembly in house"
    },

    home_Partners_10: {
        zh: "FixAid，LapAid和RectoAid的最终组装都是CarpoNovum瑞典总部的无尘间内完成，以确保达到最佳品质。实时监控的无尘环境，训练有素的瑞典专业装配技师以及在组装前后均按严格的QCP质控全检，是产品万无一失的有力保障。",
        en: "The final assembly of FixAid, LapAid and RectoAid is performed in our own cleanroom. The assembly is a relatively straight forward process but requires knowledge of the product and its use. Creating perfect conditions to conduct final assembly has been a strategic part of our efforts to reduce production costs and increase the quality of the final product. Before and during assembly we perform QCP (Quality Control Procedures) on all parts (100% control) to assure that the final product reach premium quality."
    },

    home_Partners_11: {
        zh: "周密部署的设计保护",
        en: "Risk reduction for reproduction"
    },

    home_Partners_12: {
        zh: "通过注册专利、有计划地安排及分散设计图纸、签订严格的保密协议，CarpoNovum公司在保证产品质量的同时也非常注重对产品设计上的相关保护。所有分开生产的零部件最终均运回瑞典总部进行最终QCP，激光标识，清洗以及最后组装。",
        en: "Companies that are working with suppliers and particularly suppliers from low cost countries know that there is a high risk to be reproduced, actually it is more or less compulsory that a new device will be copied. Anyone that believe differently is a fool. The only chance to avoid being copied is to spread out the manufacturing to different suppliers and manufacture different parts that has no logic connection for the subcontractor. This is how we manufacture our devices. All parts are then sent to Sweden for final QCP, laser marking, washing and final assembly. "
    },

    home_Ownership_1: {
        zh: "公司所有权",
        en: "Ownership"
    },

    home_Ownership_2: {
        zh: " 说明：",
        en: "Description:"
    },

    home_Ownership_3: {
        zh: "创始人",
        en: "Founders"
    },

    home_Ownership_4: {
        zh: "早期投资者 (IG1): 天使投资/私人投资/LUAB 隆德大学创新孵化公司",
        en: "Early Investors (IG1): Business Angels/Private Investors/LUAB"
    },

    home_Ownership_5: {
        zh: "近期投资者 (IG2): Berta Kamprad基金会/私人投资",
        en: "Recent Investors (IG2): Mrs. Berta Kamprad Foundation/Private investors"
    },

    home_Ownership_6: {
        zh: "新投资者 (IG3): 私人投资",
        en: "New Investor (IG3): Private Investor"
    },

    home_Ownership_7: {
        zh: "提名权：依据股东合约书第6条决定",
        en: "Nomination Rights: In accordance with § 6 of the Shareholders Agreement."
    },

    home_QualityAndRegulatory_1: {
        zh: "质量与法规",
        en: "Quality and Regulatory"
    },

    home_QualityAndRegulatory_2: {
        zh: "质量法规的重点主要围绕CREX系统的主要组件，包括FixAid，RapAn和相关的测试仪器。根据CarpoNovum公司于2009年2月修订过的欧洲分类决策树，这些器械被认为是短期或是暂时性的侵入性手术仪器，即II类器械（测试仪器属于I类产品）。这一分类原则上也符合美国食品药品管理局（FDA）和中国食品药品管理局（CFDA）的最新规定。",
        en: "Regulatory focus will be on the main components of the CREX System consisting of FixAid, RapAn and related Test devices. Based on CarpoNovum’s revised European classification decisions tree (February 2009), the devices are considered to be short term or transient surgical invasive devices i.e. Class IIa (while the Test device is a Class I product). USA (FDA) and China (S-FDA) apply the same definitions, but to secure the route to approval in China we are in the process to getting a definite statement from S-FDA. However we believe that the applications and S-FDA approvals is going to be a straight forward processes. In USA there are some late predicate devices, which will simplify the 510(k) process both for us as manufacturer and the FDA."
    },

    home_QualityAndRegulatory_3: {
        zh: "为了提升产品质量的国际认可度，使后续的各种行政审批更顺利，公司选择以“全质量系统路线”通过了欧洲CE认证（符合EN / ISO / 13485质量标准）。 公司的技术文件也全部达到欧盟医疗器械法规（EU Medical Device Directive, MDD）的标准要求。",
        en: "To facilitate further regulatory approvals and mutual recognition, we have decided to choose the “full quality system route” (compliance with EN/ISO/13485) for CE marking. We will also evaluate the first technical file to certify our compliance with MDD."
    },

    home_QualityPolicy_1: {
        zh: "公司质量方针",
        en: "Quality Policy"
    },

    home_QualityPolicy_2: {
        zh: "CarpoNovum致力于提供满足客户期望并符合相关监管要求的医疗设备和相关服务。",
        en: "CarpoNovum is committed to providing medical devices and associated services that meet customers’ expectations and comply with relevant regulatory requirements."
    },

    home_QualityPolicy_3: {
        zh: "CarpoNovum AB确保制定的质量方针：",
        en: "CarpoNovum AB ensures that the established Quality Policy:"
    },

    home_QualityPolicy_4: {
        zh: "与公司目标具有一致性；",
        en: "is appropriate for the purpose of the organization"
    },

    home_QualityPolicy_5: {
        zh: "达到相应要求并保持质量管理体系有效性；",
        en: "includes a commitment to comply with the requirements and to maintain the effectiveness of the quality management system"
    },

    home_QualityPolicy_6: {
        zh: "为建立和审查质量目标提供了框架；",
        en: "provides a framework for establishing and reviewing quality objectives"
    },

    home_QualityPolicy_7: {
        zh: "在公司内部内得到良性的传达和理解（所有工作人员都接受了质量方针的培训），为定期进行审查以确保已制定质量方针的适用性。",
        en: "is communicated and understood within the organization (all staff is trained in the quality policy) and is reviewed for continuing suitability"
    },

    home_QualityPolicy_8: {
        zh: "目前的质量方针如下：",
        en: "The current Quality Policy is stated as follows:"
    },

    home_QualityPolicy_9: {
        zh: "达到适用的国家法律，法规和标准的要求；",
        en: "Compliance with applicable national laws, regulations and standards."
    },

    home_QualityPolicy_10: {
        zh: "根据EN / ISO 13485建立和维护质量管理体系（QMS）；",
        en: "Establish and maintain a QMS according to EN/ISO 13485"
    },

    home_QualityPolicy_11: {
        zh: "寻求QMS认证",
        en: "Seek certification of its QMS"
    },

    home_QualityPolicy_12: {
        zh: "存档技术文件；",
        en: "Compile Technical files"
    },

    home_QualityPolicy_13: {
        zh: "与主要分包商签订合同；",
        en: "Establish contracts with main sub-contractors"
    },

    home_QualityPolicy_14: {
        zh: "确保质量方针的适用性；",
        en: "Securing suitability"
    },

    home_QualityPolicy_15: {
        zh: "确保适当数量的供应商；",
        en: "Securing an appropriate number of suppliers."
    },

    home_QualityPolicy_16: {
        zh: "在员工入职时就开始对其进行公司质量方针的培训。",
        en: "The Quality Policy is communicated to all employees during their introduction program."
    },


    home_TechnologyAndProducts_1: {
        zh: "相关背景介绍",
        en: "Technology and Products "
    },

    home_TechnologyAndProducts_2: {
        zh: "许多消化道疾病需要外科手术进行肠切除、改道、吻合重建，这也包括大肠癌手术领域。为了保证手术顺利完成，通常外科医师需要有一定空间进行操作，但这其中至少有三分之一的病例必须在低位盆腔的狭小范围内完成结肠与直肠的吻合，若使用手工缝合则存在诸多不便。为此，在半个多世纪前，圆形钉合吻合器应运而生，并逐渐成为该领域的常规手术方式。遗憾的是，钉合吻合器自身有不少限制和弊端，因为依旧运用相同机械原理，故尽管进行了不断改进，仍无法从根本上解决问题。",
        en: "Numerous diseases in the gastrointestinal tract require surgical procedures in which parts of the intestine are resected (cut off) and joined together again. One such disease is cancer in the large intestine. A majority of all colorectal cancers are treated by surgery. Colorectal cancer surgery is always time consuming and, if the anastomosis needs to be formed in the lower pelvic area, it is also very difficult for the surgeon to get sufficient access for suturing the intestine together. One third of these cases, so-called low resections, are in the lower pelvic area where surgeons need to anastomose the colon to the rectum. The anatomical difficulties have brought forward new procedures. More than half a century ago (1964) the circular stapling instrument was introduced. This was the start of a new era in the possibilities of anastomosing the colon to the rectum. The circular stapling instrument has been refined and improved since its introduction but the basic principles for the instrument remain. The use of the circular stapler for anastomosis after low resections has been the established surgical procedure for the last 45 years. Although the stapling technique is a common procedure it is associated with certain problems."
    },

    home_TechnologyAndProducts_3: {
        zh: "一些研究表明，高达30％的直肠癌患者在外科手术治疗后会发生吻合口瘘。",
        en: "Some studies claim that up to 30% of patients undergoing surgery for rectal cancer suffer from leakage in the anastomosis."
    },

    home_TechnologyAndProducts_4: {
        zh: "使用钉合吻合还会产生明显的管腔狭窄，从而导致肠腔狭窄，并因此造成患者的不便。",
        en: "The staplers can cause significant narrowing of the lumen which causes intestinal stenosis and consequently inconveniences for the patient."
    },

    home_TechnologyAndProducts_5: {
        zh: "由于术后很难监测，所以这一问题的诊断通常都存在着严重的滞后性。",
        en: "When Anastomotic leakage occurs after surgery it is difficult to detect and consequently it is a substantial doctors delay in recognition of the diagnosis."
    },

    home_TechnologyAndProducts_6: {
        zh: "正是因为吻合口瘘是使用钉合吻合技术所可能面临的最严重的问题，所以很多外科医生在做吻合手术时都会常规性的在近吻合区域做造口。根据每个患者的病情，医生决定做暂时性还是永久性的造口。无论如何，患者都要忍受身体上造口的不便，而且关闭造口的时候还要再忍受二次手术的痛苦，而新的吻合又意味着新的吻合口瘘风险。",
        en: "The most severe problem of the stapling technique is of course anastomotic leakage. As a consequence, many clinicians routinely create a protective stoma proximal to the anastomosis. This stoma may be temporary or permanent depending on the condition of the patient. Anyhow, this forces the patient not only to endure a stoma for a certain period of time but also requires a reoperation when the stoma is put down again. This implies a new anastomosis with a renewed risk for leakage. Furthermore, convincing data shows that radiotherapy before surgery will decrease local reoccurrence and increase the 5-year survival, but radiotherapy also makes the remaining tissue more vulnerable and less supportive to healing. It is highly understandably that the majority of patients want to avoid a permanent stoma and a majority of patients prefer radiotherapy before surgery. To implement these requirements most developed markets start the treatment of rectal cancer patients with radiotherapy 6-8 weeks before surgery and during surgery use staplers to create an anastomosis and a temporary protective stoma at the level of the small intestine in order to reduce the risk of anastomotic leakage. Due to this established method 80-90% of all low rectal cancer patients will get a temporary stoma. In spite of this precaution with a stoma around 10% of the patients with a stapled anastomosis will develop a leakage and require additional treatment on the ward or the intensive care unit. Moreover, most of the patients with a temporary stoma will undergo surgery again within 2-4 months in order to close the stoma."
    },

    home_TechnologyAndProducts_7: {
        zh: "此外，据可靠数据显示，手术前放射治疗可以减少局部复发并增加5年生存率，但放射治疗也使剩余组织更脆弱，更难愈合。",
        en: ""
    },

    home_TechnologyAndProducts_8: {
        zh: "很容易理解大多数患者想要避免永久性造口，而大部分患者也会选择在手术前接受放射治疗。为了迎合这些需求，大多数成熟的医疗市场在手术前6-8周开始放射性治疗直肠癌患者，并且在手术期间使用吻合器在小肠上做吻合和临时保护性造口，以降低吻合口瘘的风险。基于这种既定的方法，80-90％的所有低位直肠癌患者将接受临时造口。尽管采用了这一系列的预防措施，约10％的接受钉合吻合手术的患者还是会出现术后吻合口瘘，需要在病房或重症监护室进行额外的治疗。此外，大多数临时造口的患者将在2-4个月内再次接受手术，以关闭造口。",
        en: ""
    },

    home_TechnologyAndProducts_9: {
        zh: "下表的数据显示永久性造口是发生吻合口瘘几率最小的，因为避免了手术过程中的所有产生该风险的步骤。但是，不到万不得已，没有人愿意余生都带着一个极其不方便的造口生活。所以目前最主流的治疗方法仍是使用钉合吻合技术，尽管它具有一定的吻合口瘘风险。而我们的目标当然是为患者提供一种更优选择：相似优秀的手术效果，更低的吻合口瘘风险。",
        en: "The table below shows that to conduct a permanent stoma is the most safe way, since you avoid all risky parts of the operation. But nobody wants to end up with a permanent stoma if there is an option. Today the option is stapled technique even if it is a risky affair. Our goal is of course to give the patients the same opportunity but with substantially reduced risks."
    },

    home_TechnologyAndProducts_10: {
        zh: "不管是从节省医疗花费还是改善患者术后康复的角度来看，严重吻合口瘘都是医疗工作者应该尽量避免的。对于患者而言，手术后一旦发生严重吻合口瘘，不仅意味着巨大的后续医疗开支，死亡风险也大幅提高 。如果选择在首次手术时做暂时性造口来规避严重吻合口瘘，同样也会大幅增加医疗开支：延长手术时间带来的额外开支，造口三个月需要的材料费用，还有用来关闭造口的二次手术费用。此外，很多人都低估了发生术后吻合口狭窄所增加的医疗开支：大部分患者都需要终生使用粪便软化剂来帮助排便，少数患者（5%）需要重新入院接受肠道扩张治疗，其中有些排便困难严重的患者甚至面临二次手术进行永久造口这样不得已的治疗方案。",
        en: "Severe leakage is of course the most expensive drawback in all aspects and it is also associated with a high degree of mortality which is not possible to compensate. To put a relieving (temporary) stoma during the primary operation is also associated with high costs. Increased surgical time, stoma material costs for 3 months and a second operation to close the stoma. The stricture in the anastomosis is an underestimated cost. Most patient use stool softener the rest of their life and a few patients (5%) will come back to the hospital to dilatate the stricture and in some severe cases experience a new operation with a permanent stoma as a solution for a long standing problem."
    },

    home_SurgicalProcedure_1: {
        zh: "肠道器械吻合方式比对",
        en: "Surgical procedure"
    },

    home_SurgicalProcedure_2: {
        zh: "吻合术分类概述",
        en: "Some basic knowledge about various anastomotic techniques"
    },

    home_SurgicalProcedure_3: {
        zh: "A. 钉合吻合术",
        en: "A. Stapling Technology"
    },

    home_SurgicalProcedure_4: {
        zh: "外科吻合可以通过手工缝合或者机械钉合的方式来完成。钉合器已经普及超过半个世纪。这种吻合方法最主要的问题就是钉合的过程中钉合器会挤压和碾碎机体组织。钉合器本身会对机体施加一个平行四边形力F1，这会造成平行四边形范围内的组织坏死。手术后机体愈合会受到排异反应和坏死组织吞噬相邻愈合中健康组织（A）的混合干扰。这使得吻合在愈合初期（如手术后48小时）特别脆弱。此外，钉合器的使用还会造成大量的瘢痕组织。",
        en: "A surgical anastomosis can be created using suture sewn by hand and by mechanical staplers. Staplers have been well known for more than 50 years. The main problem with staplers is that they squeeze and crush the tissue during the stapling process. The stapler itself creates a parallelogram of forces F1 and the tissue trapped inside the parallelogram necrotize. The healing is disturbed by a mixture of foreign body reaction and necrotic tissue engulfing the area just adjacent to where the process of healing (A) takes place. This makes the anastomosis weak and vulnerable especially early in the healing process i.e. the first 48 hours after surgery. The healing process also launched a lot of scar tissue due to the staplers.\n"
    },

    home_SurgicalProcedure_5: {
        zh: "B. 压缩式吻合术",
        en: "B. Compression Anastomosis "
    },


    home_SurgicalProcedure_5b: {
        zh: "吻合结肠的第二种方式是使用压缩式吻合术。在这种类型的吻合中，吻合器会对整个吻合口周围组织产生一个持续挤压作用力F2，使得被挤压的组织坏死。手术后，该坏死组织会吞噬相邻的愈合中的健康组织（B），对机体愈合造成干扰。这使得压缩式吻合具有一定随意性，压缩环可能会在愈合早期脱落，留下肠道自行愈合。如果手术后肠压力高，吻合可能会特别脆弱。\n",
        en: "Another way to anastomose colon is by the use of Compression Anastomosis. In this type of anastomosis, the tissue is continually squeezed by a load F2 that affects the tissue around the whole circumference of the anastomosis. The squeezed tissue necrotizes. The healing is disturbed by necrotic tissue engulfing just adjacent to where the process of healing (B) takes place. This makes compression anastomosis arbitrary and as a consequence the compression ring comes lose early in the healing process and leaves the intestine the natural way. This may possibly make the anastomosis vulnerable especially if intestines are subjected to tension after surgery.\n"
    },


    home_SurgicalProcedure_6: {
        zh: "C. 适应性吻合术",
        en: "C. Adaptive Anastomosis"
    },

    home_SurgicalProcedure_7: {
        zh: "CarpoNovum公司研发出来的新型适应性吻合术被命名为CREX。具体说来，CREX指的是用于吻合肠管断端，可提供样品提取与分析功能并可行导管介导的X光检查的结直肠吻合环 (Colorectal anastomotic rings, Re-join the intestinal ends and validate the anastomosis, with function of Extract samples for analysis and conduct X-ray through connected catheters)。使用该吻合术吻合时，机体组织被夹在一个弹性硅胶环（6）和一个刚性塑料环（2）之间。刚性环使用卡扣功能支撑，可以根据肠断端情况进行适应调节。愈合发生区域（5）与组织坏死开始的区域（4）——例如弹性硅胶环（6）和刚性塑料环（2）之间被夹着的区域，被分隔开。由于刚性环产生的恒定距离，两个肠断端仅适合于彼此。也正因为两个刚性环之间的恒定距离，发生愈合的区域（5）的肠壁中的血液流动不会受到压力的影响。此外，刚性环内部部分（4）和愈合区域（5）之间的距离形成了导管连接到的腔室（3）。因此，可以通过使用连接的导管从腔室取样，或通过对比度和x射线来检测吻合情况。\n",
        en: "A newly developed adaptive anastomosis is named CREX. In this type of anastomosis, the tissue is squeezed between an elastic silicone ring (6) and a rigid plastic ring (2). The rigid rings are held together with a snap function and accordingly adapt to the two intestinal ends. The area where the healing process takes place (5) is separated from the area where the necrosis starts (4) i.e. the part of the intestine that is squeezed between the silicone (6) rings and the rigid rings (2). The intestinal ends are only adapted to each other as a consequence of the constant distance created by the rigid rings. The blood flow in the intestinal wall in the area where the healing takes place (5) is consequently not affected by compression due to the distance between the rigid rings. Furthermore, the distance between the rigid rings inner part (4) and the healing area (5) create a chamber (3) to which a catheter is connected. It is hence possible to take samples from the chamber by the use of the connected catheter or visualize the anastomosis by the use of contrast and x-ray.\n"
    },

    home_SurgicalProcedure_12: {
        zh: "教学视频",
        en: "Instructional videos"
    },

    home_Products_1: {
        zh: "产品介绍",
        en: "Products"
    },

    home_Products_2: {
        zh: "由CarpoNovum公司独立研发的CREX专利产品家族富含创新品质，目前在全球范围内属领先水平，在市场上无其它类似器械。与此同时，系列产品在世界主要国家均申请了完备的产品及方法的专利保护。CREX核心技术在于协助吻合手术的的短期植入环（连接环），三大吻合产品均基于此原理进行开发升级。在结直肠手术中，FixAid系列适用于结肠方面的开放术式；LapAid系列适用于结肠及直肠上段的开放及腹腔镜术式，可选择与带监测导管的CREX DMHC或不带导管的CREX DMH两种连接环配合使用；RectoAid系列适用于直肠癌相关术式，是一种非常具有潜力的独创设计，该系列很可能将对超低位直肠癌手术带来革命性影响。目前，针对LapAid和RectoAid性能的临床多中心研究正在包括瑞典、丹麦、德国、以色列及中国范围内进行中。",
        en: "CREX is fully developed by CarpoNovum. There are no similar instruments on the global market. The unique method/products are patented on all continents. The product portfolio is based on anastomotic short-term implant rings (connection rings). The rings fit three different instruments that make it possible to put the rings in place in all different parts of colon and rectum. However, FixAid is designed for open surgery on colon, LapAid for laparoscopic surgery on colon and RectoAid for rectal cancer surgery. LapAid and RectoAid are the subjects of ongoing clinical studies. The size of the intestine is possible to measure with CREX TestDevice and the connection ring has two options, with (CREX DMHC) or without (CREX DMH) catheters. CREX HealGuard has two functions, measure the pressure during surgery and check the anastomosis after surgery. All together CREX-portfolio containing seven (7) different devices and including different sizes, it adds up to seventeen instruments."
    },

    home_Products_10:{
        zh: "除此之外，作为与之相配套的相关产品还包括测量结肠管径的CREX Test Device，可与监测导管相连以用来测量术中肠吻合口压力及术后吻合口愈合情况的CREX Heal Guard。故总体上，CREX家族共七大系列共十七款不同尺寸的器械可供结直肠外科手术时充分选择。",
        en: ""
    },

    home_Products_3: {
        zh: "CREX FixAid Size 26, 29, 32",
        en: "CREX FixAid Size 26, 29, 32"
    },

    home_Products_4: {
        zh: "CREX LapAid Size 26, 29, 32",
        en: "CREX LapAid Size 26, 29, 32"
    },

    home_Products_5: {
        zh: "CREX RectoAid Size 26, 29, 32",
        en: "CREX RectoAid Size 26, 29, 32"
    },

    home_Products_6: {
        zh: "CREX TestDevice",
        en: "CREX TestDevice"
    },

    home_Products_7: {
        zh: "CREX DMHC Size 26, 29, 32",
        en: "CREX DMHC Size 26, 29, 32"
    },

    home_Products_8: {
        zh: "CREX DMH Size 26, 29, 32",
        en: "CREX DMH Size 26, 29, 32"
    },

    home_Products_9: {
        zh: "CREX HealGuard",
        en: "CREX HealGuard"
    },

    home_ClinicalTrails_1: {
        zh: "临床试验",
        en: "Clinical Trials"
    },

    home_ClinicalTrails_2: {
        zh: "CREX FixAid通过欧洲CE合格认证 (2009)",
        en: "Studies leading to CE mark for CREX FixAid (2009)"
    },

    home_ClinicalTrails_3: {
        zh: "CREX FixAid 包含了一套短期植入性外科手术器械：会短期停留在体内的植入环RapAn和辅助手术装置FixAid。RapAn和FixAid套装统称为CREX FixAid。在手术完成8-10天后机体慢慢愈合，植入环即随粪便自然排出体外。植入环上连接有4条细导管，方便医生在手术中和手术后监测肠吻合情况。公司进行了大量的动物实验（超过100头猪）和小范围的人类临床试验，初步证实了器械的安全有效性。2009年，针对欧洲CE合格认证的申请公司又做了进一步的临床试验，最终成功通过了欧洲CE合格认证。",
        en: "CREX is a procedure which uses short term implant rings (RapAn) and instruments (FixAid) which facilitates to put the rings in place in the intestine. When the healing process is complete after 8-10 days the ring will be released and follows stool out. There are four thin catheters connected to the short-term implant ring making it possible to check the anastomosis during and after surgery. After extensive animal testing, including more than 100 pigs a small study on humans, to show that the concept was reliably carried out. After this study, a second study to CE mark the product was performed 2009. "
    },

    home_ClinicalTrails_4: {
        zh: "临床试验：术后结肠镜观察研究（2010)",
        en: "Colonoscopy study on humans 8 weeks after surgery (2010)"
    },

    home_ClinicalTrails_5: {
        zh: "使用CREX方法和仪器为患者进行肠吻合手术八周后，通过结肠镜观察，吻合情况如下图左所示。其中的白色箭头显示了CREX吻合线。术后6个月后，结肠镜下就观察不到CREX吻合线了。此外，术后结肠镜观察研究形象的展示了吻合口逐渐愈合，最终恢复成正常组织的全过程。与此对照，若使用普通钉合吻合的方法进行吻合，手术后由于排异反应，吻合口会形成严重的瘢痕组织（下图中）。瘢痕组织可能会进一步导致肠腔狭窄，对患者日后的生活造成不便。如果使用手工缝合的方法进行吻合，吻合口同样也会由于术后排异反应形成一定程度的瘢痕组织（下图右）。不过，术后3-4个月以后随着缝线的消失，瘢痕组织会淡化，进入一个组织重塑的阶段。最终这种方法产生的瘢痕组织较之钉合吻合在程度上要轻许多。",
        en: "Colonoscopy 8 weeks after surgery (photos below). White arrows indicate the anastomotic line for anastomosis performed with CREX (photo to the left). After 6 months, you can’t find the anastomosis using colonoscopy. Furthermore, histologically you can visualize that the muscle layers have found their way back to normal. Anastomosis made by staplers (photo in the middle) heals with a foreign body reaction leaving severe scar tissue that may possibly causa narrowing of the intestinal lumen. A hand sewn anastomosis (photo to the right) also heals with a foreign body reaction but after 3-4 months, when stiches disappear, the foreign body reaction fade away and a remodeling phase starts. The scar tissue will not be as severe as for staplers."
    },

    home_ClinicalTrails_6: {
        zh: "CREX FixAid的产品市场分析研究（2012）",
        en: "Market analysis of CREX FixAid (2012)"
    },

    home_ClinicalTrails_7: {
        zh: "2012年，公司在瑞典，丹麦，挪威，德国，英国和中国的50家医院进行了广泛的市场调研与分析。分析结果显示：CREX产品原理确凿可靠，简便易操作，市场前景良好。不过公司还需要进一步完善产品线，开发出适用于腹腔镜手术，机器人手术和低直肠癌肿瘤手术的仪器以满足市场需求。公司董事会综合考虑了市场分析结果后，决定继续跟进产品的研发。2013年到2015年，产品的后续研发完成，相关动物实验也显示了非常出色的结果。此外， 公司对短期植入环做了细微的调整以适应新的市场需求。",
        en: "In 2012, an extensive market analysis including 50 hospitals in Sweden, Denmark, Norway, Germany, England and China was performed. The result of this analysis showed that the concept was reliable and easy to use for the surgeon. However, further instruments to CREX-portfolio had to be completed before the concept was ready for the market. Instruments that made it possible to use CREX for laparoscopic surgery, robotic surgery and surgery on low rectal cancer tumors. Considering the results from the marketing analysis, the Board took the decision that these instruments should be developed. During 2013-15, these instruments where developed and tested on animals with outstanding results. The short-term implant ring was modified to be meet the new requirements."
    },

    home_ClinicalTrails_8: {
        zh: "比较试验：CREX LapAid 与普通钉合吻合器（2014）",
        en: "Comparison study on CREX LapAid vs Staplers (2014)"
    },

    home_ClinicalTrails_9: {
        zh: "手术中和手术后监测吻合情况有几种不同方法。比较和判定这些方法的临床价值不是一件容易的事情。我们选择在手术后不同时间点（1h，12h，24h，48h和72h），以爆破压力值作为比较依据来监测术后的吻合情况（肠壁张力值大于爆破压力值，则容易发生吻合瘘）。我们的比较试验显示，使用CREX技术进行的吻合术，在手术后的所有时间点的吻合口爆破压力值都超过200毫巴，即肠壁张力值始终小于吻合口爆破压力值（下图绿色曲线） 。如果使用普通钉合吻合，则术后48小时吻合口爆破压力值明显小于200毫巴。这意味着吻合口处于脆弱状态，易发生吻合口瘘（下图红色曲线）。此外，两种吻合方式在术后7天（植入环自然脱落，随粪便排出）的吻合口爆破压力值的对比也显示，使用CREX技术吻合口更不易发生吻合口瘘。",
        en: "There are different methods available to check the strength of the anastomosis during and after surgery. It is of course difficult to evaluate the clinical value of such methods. However, we have chosen to use burst pressure, as state of the art, at different time points after surgery (1h, 12h, 24h, 48h and 72h. By doing that we have shown that the anastomosis performed by CREX (green curve, fig to the left) was stronger (more than 200 mbar) than the intestinal wall at all time points after surgery. Stapled anastomosis where fragile the first 48 hours (red curve, fig to the left). Burst pressure performed after 7 days (when the ring came loose and followed feces out) also showed that CREX was stronger than the intestinal wall. "
    },

    home_ClinicalTrails_10: {
        zh: "临床试验：CREX LapAid （2017）",
        en: "Human studies on CREX LapAid (2017)"
    },

    home_ClinicalTrails_11: {
        zh: "鉴于CREX LapAid在之前的动物试验和和比较试验中都显示了良好的试验结果，公司决定招募患者，展开了小规模的临床试验。2017年8月，20例临床试验圆满结束。试验终点为术后8-10天后，短期植入环自然脱落，随粪便排出患者体外。开展一个全新产品的临床试验，取得外科医生的认可对于试验的推进至关重要。公司十分重视临床医生的反馈，积极与第一线的工作人员沟通治疗方案，不断改进。最终，所有20例临床试验都圆满结束：没有发生任何吻合口瘘，产品安全性，有效性和方便易用性受到了一致认可。基于这一巨大成功，公司计划扩大临床试验规模至200例，新的临床试验项目将于2017年9月启动。",
        en: "Since animal studies and comparison studies showed very promising results the next step was to perform a small study on humans. At present (August 2017), a clinical study including 20 patients has just been closed. The endpoint of the study was when the short-term implant leaved the intestine after 8-10 days. However, when you perform a study with a new instrument it’s very important to get acceptance among surgeons. We have put very much efforts on accreditation and to discuss the guidelines on the ward, how to treat the patients after surgery. No leakage in anastomosis, very well accepted as an excellent functional and easy to use device. We have been doing well. In autumn (2017) a larger study including 200 patients at two different sites is taking place. "
    },

    home_ClinicalTrails_12: {
        zh: "临床试验：CREX RectoAid （2017）",
        en: "Human studies on CREX RectoAid"
    },

    home_ClinicalTrails_13: {
        zh: "CREX RectoAid的临床试验也在进行中。该仪器已经通过了中国食品药品管理局的审核。目前仪器的临床试验方案正在瑞典和中国选定试验医院经由医院伦理委员会讨论审核。该临床试验与CREX LapAid的试验方案相似，只是使用部位由结肠改为了直肠。试验终点完全一样，试验认证方案也相似。一旦该临床试验方案获得伦理委员会的批准，大概需要3个月左右完成20例试验。",
        en: "At present a clinical study with RectoAid is on track. The device is approved by the Chinese authority C-FDA and an ongoing discussion is taking place at the ethical committee at a larger hospital in China and Sweden. The study is similar to CREX LapAid study but the location of the tumor is in rectum instead of colon. The endpoints are the identical and the accreditation plans are similar to what is performed for CREX LapAid. When the study is approved by the ethical committee it will take approximately 3 months to perform the study on 20 patients. "
    },

    home_instructional_video: {
        zh: "教学视频",
        en: "Instructional Video"
    },

    home_instructional_video_1: {
        zh: "CREX-RectoAid",
        en: "CREX-RectoAid"
    },

    home_instructional_video_2: {
        zh: "CREX-FixAid",
        en: "CREX-FixAid"
    },

    home_instructional_video_3: {
        zh: "CREX-LapAid - with catheter",
        en: "CREX-LapAid - with catheter"
    },

    home_instructional_video_4: {
        zh: "CREX-LapAid - without catheter",
        en: "CREX-LapAid - without catheter"
    },

    home_instructional_video_5: {
        zh: "CREX-System",
        en: "CREX-System"
    },

    home_instructional_video_6: {
        zh: "CREX-Xray",
        en: "CREX-Xray"
    },

    instructional_video_comment: {
        zh: "请按此按钮调节适合您的分辨率",
        en: "Please adjust the resolution under this button"
    },

    contact_title: {
        zh: "联系我们",
        cn: "Contact Us"
    },

    contact_office_1:{
        zh: "办公总部",
        en: "Main Office"
    },

    contact_office_2:{
        zh: "地址 Olofsdalsvägen 10",
        en: "Olofsdalsvägen 10"
    },

    contact_office_3:{
        zh: "邮编 302 41 Halmstad",
        en: "302 41 Halmstad"
    },

    contact_office_4:{
        zh: "电话: +46-46-540 86 56",
        en: "+46-46-540 86 56"
    },

    contact_office_5:{
        zh: "邮件: info@carponovum.com",
        en: "info@carponovum.com"
    },

    contact_1:{
        zh:"Anders Grönberg",
        en:"Anders Grönberg"
    },

    contact_2:{
        zh:"MD, PhD, Senior Surgeon",
        en:"MD, PhD, Senior Surgeon"
    },

    contact_3:{
        zh:"Jonas Gulliksson",
        en:"Jonas Gulliksson"
    },

    contact_4:{
        zh:"President of Board, Intellectual Property, Attorney",
        en:"President of Board, Intellectual Property, Attorney"
    },

    contact_5:{
        zh:"Denis Viet-Jacobsen",
        en:"Denis Viet-Jacobsen"
    },

    contact_6:{
        zh:"Board member, Foreign Affairs Business Adviser",
        en:"Board member, Foreign Affairs Business Adviser"
    },

    contact_7:{
        zh:"Harald Castler",
        en:"Harald Castler"
    },

    contact_8:{
        zh:"Board member, Market analysis and business strategy",
        en:"Board member, Market analysis and business strategy"
    },

    contact_9:{
        zh:"Lars-Peter Harbing",
        en:"Lars-Peter Harbing"
    },

    contact_10:{
        zh:"Board member, Medical Device Business Adviser",
        en:"Board member, Medical Device Business Adviser"
    },

    contact_11:{
        zh:"Bengt Sjöholm",
        en:"Bengt Sjöholm"
    },

    contact_12:{
        zh:"Board member, Market analysis and business strategy",
        en:"Board member, Market analysis and business strategy"
    },

    contact_13:{
        zh:"Hans Skalin",
        en:"Hans Skalin"
    },

    contact_14:{
        zh:"Board member, Senior Foreign Affairs Business Adviser",
        en:"Board member, Senior Foreign Affairs Business Adviser"
    },

    contact_15:{
        zh:"Olof Stocksén",
        en:"Olof Stocksén"
    },

    contact_16:{
        zh:"Senior Foreign Affairs Business Adviser",
        en:"Senior Foreign Affairs Business Adviser"
    },

    contact_17:{
        zh:"Jörgen Sjöholm",
        en:"Jörgen Sjöholm"
    },

    contact_18:{
        zh:"Quality Manager",
        en:"Quality Manager"
    },

    contact_19:{
        zh:"Pontus Gedda",
        en:"Pontus Gedda"
    },

    contact_20:{
        zh:"Quality consultant",
        en:"Quality consultant"
    },

    contact_21:{
        zh:"Roland Norman",
        en:"Roland Norman"
    },

    contact_22:{
        zh:"Design and engineering",
        en:"Design and engineering"
    },

    contact_23:{
        zh:"Mattias Gellett",
        en:"Mattias Gellett"
    },

    contact_24:{
        zh:"Design and engineering consultant",
        en:"Design and engineering consultant"
    },

    contact_25:{
        zh:"Maria Djärv",
        en:"Maria Djärv"
    },

    contact_26:{
        zh:"Economic and Administration",
        en:"Economic and Administration"
    },

    contact_27:{
        zh:"Jenny Broén",
        en:"Jenny Broén"
    },

    contact_28:{
        zh:"Economic and Administration consultant",
        en:"Economic and Administration consultant"
    },

    contact_29:{
        zh:"Songen Zhang",
        en:"Songen Zhang"
    },

    contact_30:{
        zh:"MD, PhD, Clinical Study Monitor",
        en:"MD, PhD, Clinical Study Monitor"
    },

    contact_31:{
        zh:"Su Zhang",
        en:"Su Zhang"
    },

    contact_32:{
        zh:"MD, PhD, Clinical Trials Advisor",
        en:"MD, PhD, Clinical Trials Advisor"
    },

    contact_33:{
        zh:"Huijie Li",
        en:"Huijie Li"
    },

    contact_34:{
        zh:"MSc, Clinical Study Monitor",
        en:"MSc, Clinical Study Monitor"
    },

    contact_35:{
        zh:"Bohua Li",
        en:"Bohua Li"
    },

    contact_36:{
        zh:"IT Associate",
        en:"IT Associate"
    },

    news_header:{
        zh:"新闻",
        en:"News"
    },

    news_comingsoon:{
        zh:"更新中...",
        en:"Coming Soon..."
    }
};

function translate() {
    $("[translate]").map(function (i, val) {
        var index = $(val).attr("translate"),
            translate = dict[index];
        if (translate) {
            $(val).html(translate[lang]);
        }
    });
}